Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases

被引:30
|
作者
Lunkes, A
Trottier, Y
Mandel, JL
机构
[1] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France
[2] Hop Univ Strasbourg, Strasbourg, France
来源
关键词
D O I
10.1042/bse0330149
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
• HD is an autosomal dominant neurodegenerative disorder characterized by involuntary movements, cognitive impairment progressing to dementia, and mood disturbances. The brains of patients show extensive neuronal loss in the striatum, and the cerebral cortex is also affected. • The genetic defect causing HD is an expansion of a CAG repeat encoding a polyglutamine stretch in the target protein, named huntingtin. • The age of onset of HD is inversely correlated with the size of the expansion. • Polyglutamine expansion represents a novel cause of neurodegeneration, which has been shown to be responsible for seven other inherited disorders. • The polyglutamine expansion confers a gain of toxic property to the mutated target proteins. • Molecular and cellular studies of the brains of patients and of mice models of polyglutamine expansion diseases have led to the identification of abnormal intracellular inclusions representing aggregation of the mutated protein. However, the mechanism whereby such polyglutamine expansion leads to selective neuronal dysfunction and death is still puzzling.
引用
收藏
页码:149 / 163
页数:15
相关论文
共 50 条
  • [1] Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases
    Lunkes, A
    Trottier, Y
    Mandel, JL
    ESSAYS IN BIOCHEMISTRY, VOL 33: MOLECULAR BIOLOGY OF THE BRAIN, 1999, 33 : 149 - 163
  • [2] Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases
    Lunkes, A
    Yvert, G
    Trottier, Y
    Devys, D
    Mandel, JL
    NEURODEGENERATIVE DISORDERS: LOSS OF FUNCTION THROUGH GAIN OF FUNCTION, 2001, : 41 - 53
  • [3] Pathological mechanisms in polyglutamine expansion diseases
    Devys, D
    Yvert, G
    Lunkes, A
    Trottier, Y
    Mandel, JL
    NEUROPATHOLOGY AND GENETICS OF DEMENTIA, 2001, 487 : 199 - 210
  • [4] Polyglutamine expansion and Huntington's disease
    Bates, GP
    Mangiarini, L
    Wanker, EE
    Davies, SW
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1998, 26 (03) : 471 - 475
  • [5] Monomeric, Oligomeric and Polymeric Proteins in Huntington Disease and Other Diseases of Polyglutamine Expansion
    Hoffner, Guylaine
    Djian, Philippe
    BRAIN SCIENCES, 2014, 4 (01): : 91 - 122
  • [6] The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases
    Bogomazova, A. N.
    Eremeev, A., V
    Pozmogova, G. E.
    Lagarkova, M. A.
    MOLECULAR BIOLOGY, 2019, 53 (06) : 838 - 849
  • [7] The Role of Mutant RNA in the Pathogenesis of Huntington’s Disease and Other Polyglutamine Diseases
    A. N. Bogomazova
    A. V. Eremeev
    G. E. Pozmogova
    M. A. Lagarkova
    Molecular Biology, 2019, 53 : 838 - 849
  • [8] Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases
    Steffan, JS
    Thompson, LM
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (02) : 201 - 213
  • [9] Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease
    Lunkes, A
    Trottier, Y
    Fagart, J
    Schultz, P
    Zeder-Lutz, G
    Moras, D
    Mandel, JL
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1999, 354 (1386) : 1013 - 1019
  • [10] Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders
    Reis, Sara D.
    Pinho, Brigida R.
    Oliveira, Jorge M. A.
    MOLECULAR NEUROBIOLOGY, 2017, 54 (08) : 5829 - 5854